822 related articles for article (PubMed ID: 17867331)
1. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
Borowski D; Czuba B; Cnota W; Hincz P; Czekierdowski A; Gajewska J; Jaczyńska R; Ceran A; Włoch A; Wyrwas D; Wiełgoś M; Szymusik I; Szaflik K; Sodowski K
Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
[TBL] [Abstract][Full Text] [Related]
2. [Noninvasive prenatal test in the first trimester of pregnancy (NT and estimation of beta-hCG and PAPP-A) in the diagnosis of fetal abnormalities in Polish population--comparison of the biochemistry own normal ranges and literature reported data].
Mandryka-Stankewycz S; Perenc M; Dec G; Sieroszewski P
Ginekol Pol; 2009 Nov; 80(11):851-5. PubMed ID: 20088400
[TBL] [Abstract][Full Text] [Related]
3. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
4. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
5. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
6. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
[TBL] [Abstract][Full Text] [Related]
7. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
[TBL] [Abstract][Full Text] [Related]
8. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M
Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006
[TBL] [Abstract][Full Text] [Related]
9. The significance of maternal blood pregnancy-associated plasma protein A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (β-hCG) levels for the risk assessment of fetal trisomy 18 during the first prenatal testing between 11 and 13+6 weeks of pregnancy.
Ziolkowska K; Tobola-Wrobel K; Dydowicz P; Zurawski S; Pietryga M; Wysocka E
Ginekol Pol; 2020; 91(12):748-754. PubMed ID: 33447994
[TBL] [Abstract][Full Text] [Related]
10. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
[TBL] [Abstract][Full Text] [Related]
11. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
[TBL] [Abstract][Full Text] [Related]
12. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
[TBL] [Abstract][Full Text] [Related]
13. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
14. Reference centile chart for fetal nuchal translucency, maternal serum PAPP-A and free beta hCG.
Chawanpaiboon S; Cheunwattana P
J Med Assoc Thai; 2010 Feb; 93(2):154-60. PubMed ID: 20301994
[TBL] [Abstract][Full Text] [Related]
15. Medians and correction factors for biochemical and ultrasound markers in Chinese women undergoing first-trimester screening for trisomy 21.
Sahota DS; Leung TY; Fung TY; Chan LW; Law LW; Lau TK
Ultrasound Obstet Gynecol; 2009 Apr; 33(4):387-93. PubMed ID: 19306471
[TBL] [Abstract][Full Text] [Related]
16. [Effect of maternal smoking on concentrations of the pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of chorionic gonadotropin (beta hCG) in the first trimester of pregnancy].
Gajewska J; Ceran A; Chełchowska M; Borowski D; Ambroszkiewicz J; Jaczyńska R; Zwoliński J; Laskowska-Klita T
Przegl Lek; 2008; 65(10):479-82. PubMed ID: 19189527
[TBL] [Abstract][Full Text] [Related]
17. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
[TBL] [Abstract][Full Text] [Related]
18. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
[TBL] [Abstract][Full Text] [Related]
19. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
[TBL] [Abstract][Full Text] [Related]
20. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
Chen X; Chang Y; Cui HY; Ren CC; Yu BY
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
